Trial Profile

A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Corticosteroid; Cyclophosphamide; Diphenhydramine; Doxorubicin; Filgrastim; Methylprednisolone; Paracetamol; Prednisone; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms GATHER
Sponsors Genentech

03 May 2019 Results of exposure-response analysis using data from six clinical trials in patients with CD20+ B-cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN, and GAUSS) published in the British Journal of Clinical Pharmacology
13 Apr 2017 Status changed from active, no longer recruiting to completed.
10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com